INCLASS
Completed study Official Study Title A double-blind, randomized, placebo-controlled clinical study of the efficacy of INtravenous CLArithromycin as adjunctive treatment in patients with Sepsis and respiratory and multiple organ dysfunction Syndrome Brief Description INCLASS is a randomized clinical trial aiming to compare the efficacy of intravenous clarithromycin over placebo in patients with sepsis and
INTELLIGENCE-1
Completed study Official Study Title INTEgration of clinicaL and Laboratory Information to GENerate technological advanCE for the diagnosis of sepsis Brief Description INTELLIGENCE-1 is a non-interventional trial to validate the diagnostic accuracy of HemoSpec in the diagnosis of sepsis. HemoSpec is a device that integrates information of whole blood cell count, Raman spectra of
PROGRESS
Completed study Official Study Title A randomized prospective clinical trial to assess the role of PROcalcitonin-Guided antimicrobial therapy to REduce long-term infectionS Sequelae Brief Description PROGRESS is a randomized clinical trial aiming to test the efficacy of an algorithm of the duration of antimicrobial treatment based on serum procalcitonin in patients with sepsis on
PROMPT
Completed study Official Study Title Prospective Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein Assay to Indicate the Presence and Outcome of Sepsis in Patients With Suspected Infection Following Emergency Department Admission Brief Description PROMPT is a non-interventional trial aiming to validate the diagnostic accuracy of Heparin Binding Protein
IFX-1-P2.3
Completed study Official Study Title An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Details Status: Completed Study Type: Interventional (Clinical Trial) Study phase: II Study sites: 1 site in Greece Actual enrolment: 12 participants ClinicalTrials.gov Identifier: NCT03001622 EudraCT number: 2016-002988-33 National
HIDRA04
Completed study Official Study Title A double-blind, randomised, placebo-controlled clinical trial of the safety and efficacy of MABp1, a- first-in-class true human antibody targeting interleukin-1alpha, in patients with hidradenitis suppurativa not eligible for adalimumab Brief Description HIDRA04 is a double-blind randomized study aiming to the comparison of the efficacy of MABp1 (Bermekimab), a fully